New targeted drug combo aims to curb relapse in kids with rare immune disorder
NCT ID NCT07431060
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding the targeted drug luvometinib to standard chemotherapy improves outcomes for children with multisystem Langerhans cell histiocytosis (LCH), a rare immune cell disorder. About 120 children aged 0-18 with newly diagnosed, untreated LCH will be randomly assigned to receive either standard chemo alone or chemo plus luvometinib. The goal is to see if the combination reduces disease reactivation and improves survival without major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Luvometinib (a targeted cancer drug) plus chemotherapy (prednisone, vincristine, mercaptopurine)
- What this could lead to
- If successful, this combination could offer better disease control and fewer relapses for children with severe multisystem LCH.
- What could go wrong
- This is an early-stage trial with only 120 participants, so results may not apply to all children. Adding a targeted drug may also increase side effects like skin issues or high triglycerides.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, China
-
Anhui Provincial Children's Hospital
RECRUITINGHefei, China
-
Jiangxi Provincial Children's Hospital
RECRUITINGJiangxi, China
-
Kunming Children's Hospital
RECRUITINGKunming, China
-
The First Affiliated Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, China
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
-
The Second Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, China
-
West China Second Hospital, Sichuan University
RECRUITINGChengdu, China
-
Xi'an Children's Hospital
RECRUITINGXi'an, China
-
Xi'an Northwest Women's and Children's Hospital
RECRUITINGXi'an, China
-
Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital
RECRUITINGZunyi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could existing cancer drugs tackle rare tumors? new trial aims to find out
- Scientists hunt for genetic clues in rare blood disorders
- New pill could spare kids with rare bone disease from chemo
- Old drug, new hope: lenalidomide tackles rare histiocyte cancers
- New pill shows promise for rare childhood diseases
- New hope for rare cancer: drug cocktail targets stubborn LCH